跳轉至內容
Merck
全部照片(2)

重要文件

檢視所有文件

SML0061

Sigma-Aldrich

SAHA

≥98% (HPLC), powder, HDAC inhibitor

同義詞:

N-羟基-N′-苯基-辛烷二酰胺, 伏立诺他, 辛二酰苯胺异羟肟酸

登入查看組織和合約定價
全部照片(2)

About This Item

經驗公式（希爾表示法）:
C14H20N2O3
CAS號碼:
149647-78-9
分子量：:
264.32
MDL號碼:
MFCD00945317
分類程式碼代碼:
12352200
PubChem物質ID:
329825127
NACRES:
NA.77

產品名稱

SAHA, ≥98% (HPLC)

化驗

≥98% (HPLC)

形狀

powder

顏色

white to tan

溶解度

DMSO: ≥15 mg/mL

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

ONC(=O)CCCCCCC(=O)Nc1ccccc1

InChI

1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

InChI 密鑰

WAEXFXRVDQXREF-UHFFFAOYSA-N

基因資訊

human ... HDAC1(3065) , HDAC2(3066) , HDAC3(8841) , HDAC6(10013)

尋找類似的產品？ 前往 產品比較指南

應用

SAHA可用于研究基因调控、转录调控和细胞信号转导。

生化／生理作用

SAHA或Vorinostat可促进导致细胞凋亡、分化和生长停滞的基因的转录。其已在淋巴瘤中获得有益结果，但在实体瘤中没有。
伏立诺他或辛二酰苯胺异羟肟酸（SAHA）是一种有效的、可逆的泛组蛋白去乙酰化酶（HDAC）抑制剂。其可抑制I类和II类HDAC，从而改变基因转录并诱导多种转化细胞中的细胞周期停滞和/或凋亡。
有效的、可逆的泛组蛋白去乙酰化酶（HDAC）抑制剂。

特點和優勢

该化合物是基因调控研究的推荐产品。点击此处，了解更多精选基因调控产品。了解更多有关用于其他研究领域的生物活性小分子的信息，请访问 sigma.com/discover-bsm。

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H341,H360

危險分類

Muta. 2 - Repr. 1A

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
106M4705V
035M4769V
113M4752V
042M4740V
061M4742V

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Sarah W Gordon et al.
American journal of clinical oncology, 42(8), 649-654 (2019-07-16)
Preclinical data suggest histone deacetylase inhibitors improve the therapeutic index of sorafenib. A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma. Patients received vorinostat (200
Robert W Robey et al.
Molecular pharmaceutics, 8(6), 2021-2031 (2011-09-09)
The histone deacetylase inhibitors (HDIs) have shown promise in the treatment of a number of hematologic malignancies, leading to the approval of vorinostat and romidepsin for the treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell
Gloria Manzotti et al.
Journal of experimental & clinical cancer research : CR, 38(1), 346-346 (2019-08-10)
RUNX2 is a Runt-related transcription factor required during embryogenesis for skeletal development and morphogenesis of other organs including thyroid and breast gland. Consistent evidence indicates that RUNX2 expression is aberrantly reactivated in cancer and supports tumor progression. The mechanisms leading
Sachith Mettananda et al.
Scientific reports, 9(1), 11649-11649 (2019-08-14)
β-Thalassaemia is one of the most common monogenic diseases with no effective cure in the majority of patients. Unbalanced production of α-globin in the presence of defective synthesis of β-globin is the primary mechanism for anaemia in β-thalassaemia. Clinical genetic
Weiwei Yu et al.
British journal of pharmacology, 174(20), 3608-3622 (2017-07-28)
Intrinsic and/or acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) commonly occurs in patients with non-small-cell lung cancer (NSCLC). Here, we developed a combined therapy of histone deacetylase inhibition by a novel HDAC inhibitor, YF454A, with
查看所有相關論文

文章

Autophagy in Cancer Promotes Therapeutic Resistance

We presents an article on Autophagy in Cancer Promotes Therapeutic Resistance

Histone Modification and Chromatin Remodeling | Epigenetics

Epigenetic modifications are thought to occur through two key interconnected processes—DNA methylation and the covalent modification of histones.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務